BACKGROUNDOral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. This study evaluated safety and efficacy of propranolol eye micro-drops in preterm newborns with ROP.METHODSA multicenter open-label trial, planned according to the Simon optimal two-stage design, was performed to analyze safety and efficacy of propranolol micro-drops in newborns with stage 2 ROP. To this end, hemodynamic and respiratory parameters were monitored, and blood samples were collected weekly, for three weeks. Propranolol plasma levels were also monitored. The progression of the disease was evaluated with serial ophthalmologic examinations.RESULTSTwenty-three newborns were enrolled. Since the fourth of the first 19 newborns enrolled in the first stage of the study showed a progression to stage 2 or 3 with plus, the second stage was prematurely discontinued. Even though the objective to complete the second stage was not achieved, the percentage of ROP progression (26%) was similar to that obtained previously with oral propranolol administration. However, no adverse effects were observed and propranolol plasma levels were significantly lower than those measured after oral administration.CONCLUSIONPropranolol 0.1% eye micro-drops are well tolerated, but not sufficiently effective. Further studies are required to identify the optimal dose and administration schedule.
Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial / L. Filippi, G. Cavallaro, P. Bagnoli, M. Dal Monte, P. Fiorini, E. Berti, L. Padrini, G. Donzelli, G. Araimo, G. Cristofori, M. Fumagalli, G. la Marca, M. Luisa Della Bona, R. Pasqualetti, P. Fortunato, S. Osnaghi, B. Tomasini, M. Vanni, A. Maria Calvani, S. Milani, I. Cortinovis, A. Pugi, M. Agosti, F. Mosca. - In: PEDIATRIC RESEARCH. - ISSN 0031-3998. - 81:2(2017), pp. 307-314.
Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial
M. Fumagalli;S. Osnaghi;S. Milani;I. Cortinovis;F. MoscaUltimo
2017
Abstract
BACKGROUNDOral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. This study evaluated safety and efficacy of propranolol eye micro-drops in preterm newborns with ROP.METHODSA multicenter open-label trial, planned according to the Simon optimal two-stage design, was performed to analyze safety and efficacy of propranolol micro-drops in newborns with stage 2 ROP. To this end, hemodynamic and respiratory parameters were monitored, and blood samples were collected weekly, for three weeks. Propranolol plasma levels were also monitored. The progression of the disease was evaluated with serial ophthalmologic examinations.RESULTSTwenty-three newborns were enrolled. Since the fourth of the first 19 newborns enrolled in the first stage of the study showed a progression to stage 2 or 3 with plus, the second stage was prematurely discontinued. Even though the objective to complete the second stage was not achieved, the percentage of ROP progression (26%) was similar to that obtained previously with oral propranolol administration. However, no adverse effects were observed and propranolol plasma levels were significantly lower than those measured after oral administration.CONCLUSIONPropranolol 0.1% eye micro-drops are well tolerated, but not sufficiently effective. Further studies are required to identify the optimal dose and administration schedule.File | Dimensione | Formato | |
---|---|---|---|
Filippi PedRes 2016.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
5.78 MB
Formato
Adobe PDF
|
5.78 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.